Gilead Sciences Correlations
GILD Stock | USD 92.58 0.17 0.18% |
The current 90-days correlation between Gilead Sciences and Tff Pharmaceuticals is 0.26 (i.e., Modest diversification). The correlation of Gilead Sciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Gilead Sciences Correlation With Market
Modest diversification
The correlation between Gilead Sciences and DJI is 0.26 (i.e., Modest diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Gilead Sciences and DJI in the same portfolio, assuming nothing else is changed.
Gilead |
Moving together with Gilead Stock
0.64 | VTRS | Viatris | PairCorr |
0.78 | ESPR | Esperion Therapeutics Buyout Trend | PairCorr |
0.84 | EWTX | Edgewise Therapeutics | PairCorr |
0.82 | BHC | Bausch Health Companies | PairCorr |
0.83 | BMY | Bristol Myers Squibb Sell-off Trend | PairCorr |
0.74 | EBS | Emergent Biosolutions | PairCorr |
0.68 | WAT | Waters | PairCorr |
0.73 | MNMD | Mind Medicine | PairCorr |
0.89 | CPRX | Catalyst Pharmaceuticals | PairCorr |
Moving against Gilead Stock
0.84 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
0.82 | TAK | Takeda Pharmaceutical | PairCorr |
0.77 | JNJ | Johnson Johnson Sell-off Trend | PairCorr |
0.75 | HLN | Haleon plc | PairCorr |
0.75 | RDY | Dr Reddys Laboratories | PairCorr |
0.71 | LLY | Eli Lilly | PairCorr |
0.66 | ZTS | Zoetis Inc | PairCorr |
0.61 | PFE | Pfizer Inc Aggressive Push | PairCorr |
0.59 | ELAN | Elanco Animal Health | PairCorr |
0.77 | ANRO | Alto Neuroscience, | PairCorr |
0.55 | AMGN | Amgen Inc | PairCorr |
0.53 | LTRN | Lantern Pharma | PairCorr |
0.5 | ANEB | Anebulo Pharmaceuticals | PairCorr |
0.47 | TEVA | Teva Pharma Industries | PairCorr |
0.46 | SIGA | SIGA Technologies | PairCorr |
0.4 | REVB | Revelation Biosciences | PairCorr |
0.37 | DRMAW | Dermata Therapeutics | PairCorr |
0.35 | ABBV | AbbVie Inc Sell-off Trend | PairCorr |
0.34 | CTLT | Catalent | PairCorr |
Related Correlations Analysis
0.59 | 0.55 | 0.1 | -0.05 | TFFP | ||
0.59 | 0.36 | -0.62 | -0.34 | ELYM | ||
0.55 | 0.36 | 0.12 | -0.12 | INBX | ||
0.1 | -0.62 | 0.12 | 0.21 | ELVN | ||
-0.05 | -0.34 | -0.12 | 0.21 | MOLN | ||
Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Gilead Stock performing well and Gilead Sciences Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Gilead Sciences' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
---|---|---|---|---|---|---|---|---|---|---|
TFFP | 7.01 | (1.58) | 0.00 | (1.10) | 0.00 | 11.28 | 95.77 | |||
ELYM | 3.87 | (0.72) | 0.00 | 0.69 | 0.00 | 6.21 | 34.87 | |||
INBX | 2.31 | 0.09 | 0.02 | 0.26 | 2.72 | 5.54 | 16.80 | |||
ELVN | 2.01 | 0.03 | 0.01 | 0.16 | 2.18 | 5.84 | 12.96 | |||
MOLN | 4.43 | (0.08) | (0.01) | 0.07 | 4.92 | 9.38 | 52.92 |
Gilead Sciences Corporate Management
Johanna Mercier | Chief Commercial Officer | Profile | |
Michael Quigley | VP Biology | Profile | |
Linda Higgins | Innovation Research | Profile | |
Deborah Telman | General Affairs | Profile |